This, in turn, triggers the accumulation of FOXP1+Tregs via the PD-L2–RGMB axis, ultimately contributing to non-responsiveness to immunotherapy in NSCLC patients (64). Here, FOXP1 is linked to non-small cell lung carcinoma.